Skip to main content

How levosimendan can improve renal function?

The Original Article was published on 17 October 2017

In recent years, several studies have addressed the positive effects of levosimendan upon renal function. We sought to summarize the recent findings in order to understand by which mechanism levosimendan is improving renal function. In acute decompensated heart failure, levosimendan has an immediate renoprotective effect by increasing renal blood flow (RBF) through selective renal arterial and venous vasodilation [1]. In a recent randomized controlled study (RCT) comparing dobutamine and levosimendan in cardio-renal syndrome (CRS), Fedele et al. [2] were able to reproduce the results of Chen et al. [1] by measuring RBF through the renal artery [1, 2]. Fedele et al. and Chen et al. found that levosimendan increased RBF [1, 2]. But increasing RBF alone is not enough. Levosimendan and dobutamine exerted differential effects on glomerular filtration ratio (GFR). Both inotropic agents induced a renal vasodilatory effect accompanied by an increase in RBF, but while dobutamine does not change GFR, levosimendan increases GFR significantly [3]. Levosimendan preferentially causes a vasodilation of the afferent arterioles while dobutamine induces a balanced vasodilation of both afferent and efferent arterioles, thereby increasing RBF, while maintaining a constant glomerular filtration pressure [3]. Obviously, an isolated increase in GFR could jeopardize oxygenation of the medulla, which is sensitive to ischemia, given the highly oxygen-demanding sodium reabsorption process. For levosimendan, however, this is less likely to occur because it causes a balanced increase in GFR and renal oxygen delivery, as shown by the maintained renal oxygen consumption and extraction [4]. Last, a rise in central venous pressure (CVP) is an important predictor of renal dysfunction in heart failure patients [5]. Elevated CVP will increase renal venous backpressure and thus decrease renal perfusion pressure and impair renal function [5]. Compared to dobutamine, levosimendan could further reduce CVP and by this end improve renal function also, but this is not supported by the findings of Lannemyr et al. because both inotropic agents reduced CVP to a similar extent [3]. In conclusion, it is too simplistic to rely upon RBF to expect an improvement in renal function. An increase in RBF has to be accompanied by an increase in GFR but not at the cost of medullary hypoxemia, which is not the case with levosimendan. Effects on the reduction of CVP might also play a role. Finally, luxurious oxygenation of the cortex as induced by dopamine and dobutamine is completely useless for the kidney function, and again, the puzzle of improving renal function is far more complex.

Availability of data and materials

Not applicable.



Acute kidney injury


Randomized controlled study


Renal blood flow


Glomerular filtration ratio


Central venous pressure


  1. Chen QH, Zheng RQ, Lin H, Shao J, Yu JQ, Wang HL. Effect of levosimendan on prognosis in adult patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Crit Care. 2017;21(1):253. Review.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Fedele F, Bruno N, Brasolin B, et al. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281–8.

    Article  CAS  Google Scholar 

  3. Lannemyr L, Ricksten SE, Rundqvist B, Andersson B, Bartfay SE, Ljungman C, et al. Differential effects of levosimendan and dobutamine on glomerular filtration rate in patients with heart failure and renal impairment: a randomized double blind controlled trial. J Am Heart Assoc. 2018;7(16):e008455.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Redfors B, Bragadottir G, Sellgren J, Sward K, Ricksten SE. Dopamine increases renal oxygenation: a clinical study in post-cardiac surgery patients. Acta Anaesthesiol Scand. 2010;54:183–90.

    Article  CAS  Google Scholar 

  5. Chen X, Wang X, Honore PM, Spapen HD, Liu D. Renal failure in critically ill patients, beware of applying (central venous) pressure on the kidney. Ann Intensive Care. 2018;8(1):91.

    Article  PubMed  PubMed Central  Google Scholar 

Download references





Author information

Authors and Affiliations



PMH and DDB designed the paper. All authors participated in drafting and reviewing. All authors read and approved the final version of the manuscript.

Corresponding author

Correspondence to Patrick M. Honore.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This comment refers to the article available at

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Honore, P.M., Gutierrez, L.B., Redant, S. et al. How levosimendan can improve renal function?. Crit Care 23, 331 (2019).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: